Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02258828 · ClinicalTrials.gov registry record · Phase 4
An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder
A Phase 4 study, sponsored by Sriram Ramaswamy.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT02258828 is a Phase 4 study that has completed, run by Sriram Ramaswamy. The registered enrollment target is 26 participants.
The verdict
NCT02258828, a Phase 4 study, has completed, sponsored by Sriram Ramaswamy.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
Twenty six veterans with PTSD and cognitive impairment received 16 weeks of memantine in an open label fashion. Cognition was assessed using the Spatial Span, Logical Memory I, and Letter-Number Sequencing subtests of the Wechsler Memory Scale III (Third edition) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). RBANS measures attention, language, visuospatial skills, and immediate and delayed memories. The Clinician Administered PTSD Scale (CAPS), Hamilton Depression Scale (HAM-D), Hamilton Anxiety Scale (HAM-A), Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), and Sheehan Disability Scale (SDS) were used to assess improvement in PTSD symptoms, as secondary outcome measures.
Interventions
- DRUG Placebo
- DRUG Memantine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2005-07 |
| Est. Completion | 2007-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02258828
The ClinicalTrials.gov registry entry for NCT02258828 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sriram Ramaswamy, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02258828 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02258828 about?
NCT02258828 is a clinical study titled "An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder". Twenty six veterans with PTSD and cognitive impairment received 16 weeks of memantine in an open label fashion. Cognition was assessed using the Spatial Span, Logical Memory I, and Letter-Number Sequencing subtests of the Wechsler Memory Scale III (Third edition) and the Repeatable Battery for the A...
What is the current status of trial NCT02258828?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2005-07. Estimated completion is 2007-03.
What interventions are being tested in trial NCT02258828?
The interventions under investigation include: Placebo (DRUG), Memantine (DRUG).
Who is sponsoring clinical trial NCT02258828?
This trial is sponsored by Sriram Ramaswamy, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.